Mobia Medical (NASDAQ:MOBI) Insider Chase Leavitt Buys 2,000 Shares of Stock

Mobia Medical, Inc. (NASDAQ:MOBI) insider Chase Leavitt acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average price of $10.30 per share, with a total value of $20,600.00. Following the acquisition, the insider owned 5,000 shares in the company, valued at $51,500. This trade represents a 66.67% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mobia Medical Stock Up 7.4%

Shares of Mobia Medical stock opened at $10.77 on Wednesday. The company has a quick ratio of 12.80, a current ratio of 13.28 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $11.48. Mobia Medical, Inc. has a 52 week low of $9.85 and a 52 week high of $15.29. The company has a market cap of $358.53 million and a P/E ratio of -0.53.

Mobia Medical (NASDAQ:MOBI) last issued its earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The business’s revenue was up 102.4% compared to the same quarter last year. As a group, research analysts anticipate that Mobia Medical, Inc. will post -2.63 earnings per share for the current year.

Institutional Trading of Mobia Medical

An institutional investor recently bought a new stake in Mobia Medical stock. Citadel Advisors LLC acquired a new position in Mobia Medical, Inc. (NASDAQ:MOBI) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $670,000. Citadel Advisors LLC owned approximately 0.15% of Mobia Medical at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MOBI shares. JPMorgan Chase & Co. increased their target price on Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Bank of America began coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and set a $19.00 price objective on shares of Mobia Medical in a research report on Wednesday, August 12th. The Goldman Sachs Group initiated coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 target price on the stock. Finally, Weiss Ratings began coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.